Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphenadione is a synthetic indandione anticoagulant and vitamin K antagonist primarily used as a rodenticide to control rats, mice, voles, ground squirrels, and other rodents. It acts by inhibiting the synthesis of vitamin K-dependent clotting factors in the liver, leading to impaired blood coagulation and ultimately causing death from internal bleeding. Diphenadione has a longer half-life than warfarin and other first-generation anticoagulants, making it more persistent in animal tissues. It is considered highly toxic to mammals—including humans—by all routes of exposure. In addition to its use in rodent control worldwide, it has also been used in South America for controlling vampire bat populations[1][4][7]. The primary mechanism of action is inhibition of prothrombin formation via antagonism of vitamin K[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphenadione.